BACKGROUND: Mohs micrographic surgery (MMS) is gaining acceptance as a treatment for lentigo maligna (LM) and lentigo maligna melanoma (LMM), especially with the use of melanocyte-staining immunohistochemical (IHC) stains. In 2006, we reported our 4-year experience with Mel-5 immunostaining, with only one recurrence noted in 200 patients after a mean follow-up of 38.4 months.(1) OBJECTIVES: We present an update regarding our 13-year experience with the use of Mel-5. METHODS AND MATERIALS: Patients with primary or recurrent LM or LMM (n = 260) underwent MMS with Mel-5; 174 were followed up to evaluate for recurrence, with a mean follow-up of 34 months. The 200 patients described in the initial case series from 1999 to 2003 were also followed. RESULTS: Of the 460 patients treated from January 1999 to December 2011, five recurrences were noted in four patients; one in the initial case series and four in this new, updated series, including one re-recurrence from the initial series. One melanoma-related death occurred in a patient intermittently lost to follow-up. CONCLUSION: MMS with Mel-5 immunostaining continues to yield excellent results in the treatment of LM and LMM.
BACKGROUND: Mohs micrographic surgery (MMS) is gaining acceptance as a treatment for lentigo maligna (LM) and lentigo maligna melanoma (LMM), especially with the use of melanocyte-staining immunohistochemical (IHC) stains. In 2006, we reported our 4-year experience with Mel-5 immunostaining, with only one recurrence noted in 200 patients after a mean follow-up of 38.4 months.(1) OBJECTIVES: We present an update regarding our 13-year experience with the use of Mel-5. METHODS AND MATERIALS: Patients with primary or recurrent LM or LMM (n = 260) underwent MMS with Mel-5; 174 were followed up to evaluate for recurrence, with a mean follow-up of 34 months. The 200 patients described in the initial case series from 1999 to 2003 were also followed. RESULTS: Of the 460 patients treated from January 1999 to December 2011, five recurrences were noted in four patients; one in the initial case series and four in this new, updated series, including one re-recurrence from the initial series. One melanoma-related death occurred in a patient intermittently lost to follow-up. CONCLUSION: MMS with Mel-5 immunostaining continues to yield excellent results in the treatment of LM and LMM.
Authors: Sheila M Valentín-Nogueras; David G Brodland; John A Zitelli; Lorena González-Sepúlveda; Cruz M Nazario Journal: Dermatol Surg Date: 2016-06 Impact factor: 3.398
Authors: Joshua B Wilson; Hobart W Walling; Richard K Scupham; Andrew K Bean; Roger I Ceilley; Kirsten E Goetz Journal: J Clin Aesthet Dermatol Date: 2016-06-01
Authors: Luiz Guilherme Martins Castro; Maria Cristina Messina; Walter Loureiro; Ricardo Silvestre Macarenco; João Pedreira Duprat Neto; Thais Helena Bello Di Giacomo; Flávia Vasques Bittencourt; Renato Marchiori Bakos; Sérgio Schrader Serpa; Hamilton Ometto Stolf; Gabriel Gontijo Journal: An Bras Dermatol Date: 2015 Nov-Dec Impact factor: 1.896
Authors: Jeremy R Etzkorn; Joseph F Sobanko; Thuzar M Shin; Rosalie Elenitsas; Emily Y Chu; Joel M Gelfand; David J Margolis; Jason G Newman; Hayley Goldbach; Christopher J Miller Journal: Dermatol Surg Date: 2016-04 Impact factor: 3.398